vs
Cardlytics, Inc.（CDLX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Cardlytics, Inc.的季度营收约是REGENXBIO Inc.的1.7倍（$50.9M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs -25.5%），Cardlytics, Inc.自由现金流更多（$13.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -9.6%）
Cardlytics是一家领先的购买智能与广告技术企业，与多家大型银行合作分析匿名消费者交易数据，为消费品牌、零售商及服务商提供基于真实消费行为的精准效果广告投放服务，核心业务覆盖北美与英国地区。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CDLX vs RGNX — 直观对比
营收规模更大
CDLX
是对方的1.7倍
$30.3M
营收增速更快
RGNX
高出68.5%
-25.5%
自由现金流更多
CDLX
多$65.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-9.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.9M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -12.0% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | -25.5% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-0.15 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDLXRGNX
| Q4 25 | $50.9M | $30.3M | ||
| Q3 25 | $47.0M | $29.7M | ||
| Q2 25 | $58.0M | $21.4M | ||
| Q1 25 | $56.4M | $89.0M | ||
| Q4 24 | $68.3M | $21.2M | ||
| Q3 24 | $61.1M | $24.2M | ||
| Q2 24 | $64.0M | $22.3M | ||
| Q1 24 | $62.2M | $15.6M |
净利润CDLXRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-72.7M | $-61.9M | ||
| Q2 25 | $-9.3M | $-70.9M | ||
| Q1 25 | $-13.3M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-145.2M | $-59.6M | ||
| Q2 24 | $-4.3M | $-53.0M | ||
| Q1 24 | $-24.3M | $-63.3M |
毛利率CDLXRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CDLXRGNX
| Q4 25 | -12.0% | -190.0% | ||
| Q3 25 | -146.6% | -176.3% | ||
| Q2 25 | -22.0% | -296.3% | ||
| Q1 25 | -24.9% | 13.6% | ||
| Q4 24 | -12.2% | -242.1% | ||
| Q3 24 | -243.1% | -256.6% | ||
| Q2 24 | -24.7% | -251.3% | ||
| Q1 24 | -36.7% | -408.8% |
净利率CDLXRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -154.7% | -208.3% | ||
| Q2 25 | -16.0% | -331.8% | ||
| Q1 25 | -23.5% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -237.6% | -246.3% | ||
| Q2 24 | -6.7% | -237.7% | ||
| Q1 24 | -39.0% | -405.4% |
每股收益（稀释后）CDLXRGNX
| Q4 25 | $-0.15 | $-1.30 | ||
| Q3 25 | $-1.36 | $-1.20 | ||
| Q2 25 | $-0.18 | $-1.38 | ||
| Q1 25 | $-0.26 | $0.12 | ||
| Q4 24 | $-0.36 | $-0.99 | ||
| Q3 24 | $-2.90 | $-1.17 | ||
| Q2 24 | $-0.09 | $-1.05 | ||
| Q1 24 | $-0.56 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $48.7M | $230.1M |
| 总债务越低越好 | $212.6M | — |
| 股东权益账面价值 | $-6.5M | $102.7M |
| 总资产 | $285.6M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDLXRGNX
| Q4 25 | $48.7M | $230.1M | ||
| Q3 25 | $44.0M | $274.2M | ||
| Q2 25 | $46.7M | $323.3M | ||
| Q1 25 | $52.0M | $267.9M | ||
| Q4 24 | $65.6M | $234.7M | ||
| Q3 24 | $67.0M | $255.5M | ||
| Q2 24 | $71.2M | $290.4M | ||
| Q1 24 | $97.8M | $338.7M |
总债务CDLXRGNX
| Q4 25 | $212.6M | — | ||
| Q3 25 | $214.6M | — | ||
| Q2 25 | $214.3M | — | ||
| Q1 25 | $213.9M | — | ||
| Q4 24 | $213.6M | — | ||
| Q3 24 | $213.2M | — | ||
| Q2 24 | $212.9M | — | ||
| Q1 24 | $257.9M | — |
股东权益CDLXRGNX
| Q4 25 | $-6.5M | $102.7M | ||
| Q3 25 | $-4.7M | $161.5M | ||
| Q2 25 | $58.7M | $213.7M | ||
| Q1 25 | $64.1M | $274.2M | ||
| Q4 24 | $70.0M | $259.7M | ||
| Q3 24 | $69.7M | $301.4M | ||
| Q2 24 | $210.0M | $348.3M | ||
| Q1 24 | $199.1M | $390.7M |
总资产CDLXRGNX
| Q4 25 | $285.6M | $453.0M | ||
| Q3 25 | $292.8M | $525.2M | ||
| Q2 25 | $361.1M | $581.0M | ||
| Q1 25 | $369.1M | $490.9M | ||
| Q4 24 | $392.7M | $466.0M | ||
| Q3 24 | $399.4M | $519.1M | ||
| Q2 24 | $534.4M | $569.4M | ||
| Q1 24 | $569.0M | $629.2M |
负债/权益比CDLXRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.65× | — | ||
| Q1 25 | 3.34× | — | ||
| Q4 24 | 3.05× | — | ||
| Q3 24 | 3.06× | — | ||
| Q2 24 | 1.01× | — | ||
| Q1 24 | 1.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $13.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 25.5% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $8.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CDLXRGNX
| Q4 25 | $13.0M | $-52.3M | ||
| Q3 25 | $1.8M | $-56.0M | ||
| Q2 25 | $1.2M | $-49.3M | ||
| Q1 25 | $-6.7M | $33.6M | ||
| Q4 24 | $3.0M | $-31.6M | ||
| Q3 24 | $1.4M | $-40.5M | ||
| Q2 24 | $4.4M | $-45.5M | ||
| Q1 24 | $-17.6M | $-55.5M |
自由现金流CDLXRGNX
| Q4 25 | $13.0M | $-52.8M | ||
| Q3 25 | $1.7M | $-56.5M | ||
| Q2 25 | $903.0K | $-49.7M | ||
| Q1 25 | $-6.8M | $32.6M | ||
| Q4 24 | $2.9M | $-32.7M | ||
| Q3 24 | $878.0K | $-40.9M | ||
| Q2 24 | $4.1M | $-46.0M | ||
| Q1 24 | $-18.3M | $-56.0M |
自由现金流率CDLXRGNX
| Q4 25 | 25.5% | -174.0% | ||
| Q3 25 | 3.7% | -189.9% | ||
| Q2 25 | 1.6% | -232.8% | ||
| Q1 25 | -12.1% | 36.6% | ||
| Q4 24 | 4.2% | -154.2% | ||
| Q3 24 | 1.4% | -168.9% | ||
| Q2 24 | 6.5% | -206.2% | ||
| Q1 24 | -29.4% | -358.5% |
资本支出强度CDLXRGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 0.2% | 5.1% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 0.4% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率CDLXRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDLX
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
